Tags

Type your tag names separated by a space and hit enter

[Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?].
Braz J Psychiatry 2010; 32 Suppl 1:S7-14BJ

Abstract

OBJECTIVE

The present review provides a brief introduction into the endocannabinoid system and discusses main strategies of pharmacological interventions.

METHOD

We have reviewed the literature relating to the endocannabinoid system and its pharmacology; both original and review articles written in English were considered.

DISCUSSION

Cannabinoids are a group of compounds present in Cannabis Sativa (hemp), such as Delta(9)-tetrahydrocannabinol, and their synthetic analogues. Research on their pharmacological profile led to the discovery of the endocannabinoid system in the mammalian brain. This system comprises at least two G-protein coupled receptors, CB(1) and CB(2), their endogenous ligands (endocannabinoids; e.g. the fatty acid derivatives anandamide and 2-arachydonoyl glycerol), and the enzymes responsible for endocannabinoid synthesis and catabolism. Endocannabinoids represent a class of neuromessengers, which are synthesized on demand and released from post-synaptic neurons to restrain the release of classical neurotransmitters from pre-synaptic terminals. This retrograde signalling modulates a variety of brain functions, including anxiety, fear and mood, whereby activation of CB(1) receptors was shown to exert anxiolytic-and antidepressant-like effects in preclinical studies.

CONCLUSION

Animal experiments suggest that drugs promoting endocannabinoid action may represent a novel strategy for the treatment of depression and anxiety disorders.

Authors+Show Affiliations

Programa de pós-graduação em Neurociências, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't
Review

Language

por

PubMed ID

20512266

Citation

Saito, Viviane M., et al. "[Pharmacological Exploitation of the Endocannabinoid System: New Perspectives for the Treatment of Depression and Anxiety Disorders?]." Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999), vol. 32 Suppl 1, 2010, pp. S7-14.
Saito VM, Wotjak CT, Moreira FA. [Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?]. Braz J Psychiatry. 2010;32 Suppl 1:S7-14.
Saito, V. M., Wotjak, C. T., & Moreira, F. A. (2010). [Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?]. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999), 32 Suppl 1, pp. S7-14.
Saito VM, Wotjak CT, Moreira FA. [Pharmacological Exploitation of the Endocannabinoid System: New Perspectives for the Treatment of Depression and Anxiety Disorders?]. Braz J Psychiatry. 2010;32 Suppl 1:S7-14. PubMed PMID: 20512266.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?]. AU - Saito,Viviane M, AU - Wotjak,Carsten T, AU - Moreira,Fabrício A, PY - 2010/6/1/entrez PY - 2010/6/1/pubmed PY - 2011/2/4/medline SP - S7 EP - 14 JF - Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) JO - Braz J Psychiatry VL - 32 Suppl 1 N2 - OBJECTIVE: The present review provides a brief introduction into the endocannabinoid system and discusses main strategies of pharmacological interventions. METHOD: We have reviewed the literature relating to the endocannabinoid system and its pharmacology; both original and review articles written in English were considered. DISCUSSION: Cannabinoids are a group of compounds present in Cannabis Sativa (hemp), such as Delta(9)-tetrahydrocannabinol, and their synthetic analogues. Research on their pharmacological profile led to the discovery of the endocannabinoid system in the mammalian brain. This system comprises at least two G-protein coupled receptors, CB(1) and CB(2), their endogenous ligands (endocannabinoids; e.g. the fatty acid derivatives anandamide and 2-arachydonoyl glycerol), and the enzymes responsible for endocannabinoid synthesis and catabolism. Endocannabinoids represent a class of neuromessengers, which are synthesized on demand and released from post-synaptic neurons to restrain the release of classical neurotransmitters from pre-synaptic terminals. This retrograde signalling modulates a variety of brain functions, including anxiety, fear and mood, whereby activation of CB(1) receptors was shown to exert anxiolytic-and antidepressant-like effects in preclinical studies. CONCLUSION: Animal experiments suggest that drugs promoting endocannabinoid action may represent a novel strategy for the treatment of depression and anxiety disorders. SN - 1516-4446 UR - https://www.unboundmedicine.com/medline/citation/20512266/abstract/[Pharmacological_exploitation_of_the_endocannabinoid_system:_new_perspectives_for_the_treatment_of_depression_and_anxiety_disorders]_ L2 - http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462010000500004&lng=en&nrm=iso&tlng=en DB - PRIME DP - Unbound Medicine ER -